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Abstract
Background:  Researchers may embark on a genome-wide association study before fully
investigating candidate regions which have been reported to produce evidence to suggest that they
harbour susceptibility loci. If the genome wide study had not been carried out then results which
demonstrated only modest statistical significance from candidate regions would be judged to be of
interest and would stimulate further investigation. However if hundreds of thousands of markers
are typed then inevitably very large numbers of such results will occur by chance and those from
candidate regions may attract no special attention.
Results: An approach is proposed in which differential treatment is afforded to markers from
candidate regions and from those that are routinely typed in the context of a genome wide scan.
Different prior probabilities are assigned to the two types of marker. A likelihood ratio is derived
from the reported p value for each marker, calculated as LR = echiinv(1,p)/2, and the posterior odds
in favour of a true positive association are obtained. These odds can be used to rank the markers
with a view to suggesting the regions in which further genotyping is indicated. We suggest that prior
probabilities be specified such that a candidate marker significant at p = 0.01 and a routine marker
significant at p = 0.00001 will yield similar values for the posterior odds. We show that this can be
achieved by setting a value for prior probability of association to 0.1 for candidate markers and to
0.00018 for routine markers.
Conclusion:  It is essential that formal procedures be adopted in order to avoid modestly
positively results from candidate regions being swamped by the huge number of nominally
significant results which will be obtained when very many markers are genotyped. Software to carry
out the conversion from p values to posterior odds is available from http://www.mds.qmul.ac.uk/
statgen/grpsoft.html.
Background
The ability to carry out so-called genome wide association
studies using a standard panel of single nucleotide poly-
morphisms (SNPs) presents obvious difficulties. For
many diseases it will be the case that particular genes have
already been implicated as possibly or probably being
involved. Typically, there will be some positive and some
negative association studies, some groups will report pos-
itive results with particular markers or haplotypes while
others will report negative results with those markers but
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positive results from some other markers nearby and a
third set of groups will report positive results with a differ-
ent, though related, phenotype. There may be general con-
sensus that the gene is worthy of further investigation. In
an ideal world groups possessing appropriate datasets
would test additional polymorphisms within the gene in
an attempt to provide some definitive answer as to
whether or not it influences susceptibility. However, the
world is not ideal and instead what may happen is that
groups who have yet to fully investigate the gene may sub-
mit their datasets for genotyping with a standard, very
large, set of SNPs which will include a few markers located
in the gene in question along with a few hundred thou-
sand which are not. The problem is that markers in the
candidate gene may produce relatively modest evidence in
favour of association, perhaps at the level of p < 0.01 or so,
even with hundreds of subjects. If one were to study a can-
didate gene on its own and obtain results of this nature
one might declare them of interest and as supporting fur-
ther investigation. However if a genome wide scan of 500
K markers is performed then one can expect 5,000 to be
significant at p < 0.01 and the evidence supporting the
candidate gene will look very unimpressive indeed.
We should emphasise at this point that a marker having a
real, but modest, effect is not expected to produce a
smaller p value than markers producing apparently signif-
icant results by chance. If the expected significance, based
on effect size and sample size, for a given truly associated
marker is 0.01 then the p value actually obtained will
probably be fairly close to this value. However among 500
K markers one may expect 50 or so to be significant at p <
0.0001 by chance and there is no reason to suppose that
any of these will represent a true positive effect. If there are
particular markers which are incorporated in the genome
scan which do happen to be strongly associated with the
disease then it is true that they may produce very highly
significant p values. However our concern is that markers
which are truly associated to some degree may yield only
modest  p  values [1,2] and that their effect may be
swamped if they are considered alongside the large
number of other markers which are genotyped.
We propose that formal methods should be used for treat-
ing markers in candidate regions which have been previ-
ously implicated in a different fashion from the many
thousands of SNPs spread across the genome which will
be routinely typed in the course of a genome scan. One
approach which would be theoretically sound would be
to declare in advance a set of genes, and hence markers,
which one regarded as being worthy of special considera-
tion and to go on to analyse them first, before giving any
consideration to those routinely genotyped. One could go
on to publish the results from these analyses before ana-
lysing the other markers. However we believe that in prac-
tice it would be difficult to implement this approach.
Typically, when a genome scan is performed all markers
are analysed at once. It would be difficult to persuade
readers and reviewers that special attention should be
paid to certain markers giving results at p < 0.01 when one
has the results for 5,000 more which are just as significant.
One approach which is relevant in this context is to esti-
mate the false positive report probability (FPRP) [3]. This
aims to use the prior probability for a marker to be asso-
ciated in order to come up with a threshold p value such
that markers achieving that threshold will have less than
the declared probability of being false positive. Guidelines
have been proposed in which candidate genes and
genome screens can be treated differently when the FPRP
approach is applied in order to satisfy different criteria for
a finding to be "considered noteworthy" [4]. However
these guidelines did not explicitly tackle the issue of deal-
ing with candidate gene polymorphisms genotyped
within the context of a genome wide association study. An
alternative suggestion was to carry out weighting using the
results of previous linkage studies [5]. This used a quanti-
tative score in favour of linkage as a weighting factor,
rather than declaring particular genes or markers as being
a priori of interest.
We believe that the FPRP approach is not quite correct
from a conceptual point of view when assessing the results
of genome wide association studies. One reason is that
such a study must always be regarded as an intermediate
step. This is because the polymorphisms which are geno-
typed have been selected on the grounds of being appro-
priately spaced or because they tag other markers but they
are not themselves expected to directly influence suscepti-
bility to a disease. Rather, it is hoped that a genotyped
marker showing association with the phenotype may be
in linkage disequilibrium with a polymorphism which
does influence susceptibility. Thus a positive finding
should lead on to further genotyping of other polymor-
phisms in the region. In this situation, there is no point in
fretting over what the probability is that one has a "note-
worthy" finding. Once the scan has been performed one
will inevitably want to go on to perform further genotyp-
ing and the question will be which regions appear the
most promising to pursue. Thus the aim of the scan is to
assist in the ranking of regions for further genotyping
rather than to come up with any definitive answers as to
whether particular regions are implicated or not. Once
reasonable attempts have been made to type all available
polymorphisms within a region then one can address the
question of the overall strength of evidence in favour of
association. One can then make a judgement as to
whether it is worth proceeding to more demanding inves-
tigations such as functional studies. At this point one may
feel that a method which explicitly aims to quantify theBMC Genetics 2007, 8:20 http://www.biomedcentral.com/1471-2156/8/20
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probability that a finding represents a true positive is of
value. However we do not believe that such judgements
are necessary when the question is not whether, but
where, to perform further genotyping. Additional disad-
vantages of the FPRP approach are that one needs to
declare the power of each test, that is the probability that
a marker near a susceptibility locus will support associa-
tion at a certain significance level, and that one must
declare a plausible prior probability for each marker being
truly associated. It is doubtful whether either of these val-
ues can be realistically quantified but the application of
FPRP seems to yield an artificially concrete estimate of a
probability which is in reality quite uncertain.
An alternative approach using a Bayesian strategy has
been proposed which uses the prior probability for a test
to detect association in order to weight the p  value
obtained [6]. The weighting scheme given as an example
uses the number of potentially pathogenic polymor-
phisms detected by each tagging marker or group of mark-
ers to accord more weight to more informative markers
although other weighting schemes are suggested, for
example considering whether or not an SNP is coding or
lies under a linkage peak. Deriving the necessary weights
is mathematically relatively complex compared to the
simple scheme we describe below.
Here we propose a related method which pragmatically
seeks to rank results in a comparative way rather than to
come up with absolute judgements as to whether they
reflect true or false positive results. It also explicitly aims
to afford special treatment for already implicated candi-
date genes within the context of a genome wide associa-
tion study. Although it utilises "prior probabilities" for
association of markers within candidate genes and of rou-
tinely typed markers it is recognised that these probabili-
ties are essentially arbitrary and they are used mainly as a
way of distinguishing the two sets of markers. It does not
require any assumptions about the genetic effect size or
power to detect association.
Results
The procedure we arrive at consists of a number of stages.
The first, and perhaps most problematic, step is to divide
the markers into those which are candidate markers and
those which are routinely genotyped. Candidate markers
must either all be declared in advance or must be defina-
ble by some explicit rule. They must not have been already
typed in the current sample. (Markers which have not
been previously typed but which are in linkage disequilib-
rium with markers which have produced positive results
in the current sample must be treated as a special case.)
The authors reporting the study must report the basis on
which they have declared markers as candidates. An exam-
ple of a rule for defining a candidate marker might be to
say that one will include all markers within 200 kb of a
gene which has shown evidence from either three studies
at p < 0.01, two at 0.001 or one at 0.0001 and for which
the ratio of negative to positive association studies does
not exceed 2:1. We believe that such a rule might reason-
ably reflect how association studies are commonly inter-
preted but we emphasise that any rule can be chosen, as
long as it is explicit. Of course, one could set up hierar-
chies of candidate regions, whereby some were regarded
as more strongly supported than others, but given the dif-
ficulty in making firm judgements about the weight of evi-
dence any particular study provides we doubt that such
complex schemes would be justified.
Next, appropriate values for the prior probabilities, and
hence odds, of association for candidate and routinely
typed markers should be chosen. From the argument set
out in the Methods section we would suggest prior proba-
bilities of PPrCAND = 0.1 and PPrROUT = 0.00018 but obvi-
ously these values are to a large extent arbitrary.
Finally, for each marker and the p value we obtain for it we
write:
OPo = OPr* echiinv(p,1)/2
We can use either OPrCAND = PPrCAND/(1-PPrCAND) or
OPrROUT = PPrROUT/(1-PPrROUT) as the prior odds depend-
ing on how we have categorised the marker and we can
then go ahead to rank all results according to the posterior
odds of association. If we wish to obtain the posterior
probability rather than odds we can write ProbPo = OPo/
(OPo+1), which for the example above is equal to 0.755
for either the candidate marker significant at 0.01 or the
routine marker significant at 0.00001. However we again
emphasise that we do not regard the posterior odds or
probability as representing an absolute value but rather as
acting as a means to rank the results from different mark-
ers in order to guide further investigation.
Conclusion
The main emphasis of our proposal is that approaches are
adopted which provide differential treatment to markers
in candidate genes and those which are routinely geno-
typed within a genome wide association study. Although
we do not think the differences are critically important,
our procedure does involve a slightly different emphasis
from the FPRP approach. In order to obtain a value for the
FPRP one must declare the power of the test to detect asso-
ciation. We believe it is fair to say that in most circum-
stances, at least within the context of markers typed
routinely in the context of a genome scan, one can say
nothing about the minimum value for the true genetic
effect. Yet if the power of the test is declared to be higher
than it actually is then the FPRP value will be too low.BMC Genetics 2007, 8:20 http://www.biomedcentral.com/1471-2156/8/20
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Ultimately, if the true genetic effect is minimal and the
power to detect it is close to zero then the actual probabil-
ity that one has a false positive finding will be close to one
– all positives will be false positives. Yet a value for the
FPRP based on some over-optimistic assessment of power
may be quite small. We believe that in practice the value
calculated for the FPRP may well not reflect the true prob-
ability that a finding is a false positive.
The alternative approach which we suggest does not
require that any value for the power be specified. Rather,
our method explicitly use a "best case" scenario. Rather
than take the likelihood for the observations conditional
on a pre-specified alternative hypothesis, our approach
considers the alternative hypothesis which provides the
best fit to the data, the maximum likelihood hypothesis.
The criticism of this approach would be that it does not
represent a true Bayesian scenario in which explicit state-
ments are made about the prior probabilities of alterna-
tive hypotheses and the associated likelihoods of the
observed data. The advantage of the approach is that it is
not sensitive to any user-defined values regarding the
genetic model, linkage disequilibrium parameters, sample
size and associated power. It always explicitly deals with
the alternative hypothesis which, post hoc, is determined
to best fit the data. We have emphasised throughout that
we would not regard the posterior odds or probability
arising from this approach as truly reflecting the actual
chances that a locus is involved in susceptibility. We
believe that the FPRP value is in more danger of such a lit-
eral interpretation. In order to avoid such a literal inter-
pretation we suggest that in applying our approach it may
be preferable to quote the posterior "odds in favour of
association" rather than "probability of association". That
said, we do offer another approach to interpreting the pos-
terior odds or probability obtained from our procedure.
We suggest that it might be explicitly recognised as repre-
senting a best case scenario. Thus, if we were obtain a pos-
terior probability of association of 0.75 we might make a
statement along the lines of "the probability that this
result reflects a true positive association is no more than
0.75". Arguing along these lines, we could say that the
FPRP approach seeks to declare an estimate for the proba-
bility that a result is a false positive whereas ours seeks to
declare a minimum probability for a result being a false
positive, with fewer prior assumptions. We emphasise
that we do not regard this distinction as critical.
What we do regard as being of critical importance is to
have some formal, public system for treating results from
candidate regions differently from routinely typed mark-
ers within the context of whole genome scans. Whether
our method or FPRP or some related procedure is used, it
is essential that markers from candidate regions can be
treated as special cases. If this is not done then important
findings from such markers will be swamped. Large sam-
ples will typically have been collected over a number of
years at considerable effort. Once they have been geno-
typed for hundreds of thousands of markers they will be
at risk as being regarded as "burned out". Any subsequent
studies carried out on these samples yielding modest p
values will be overshadowed by the huge numbers of gen-
otypes already obtained. There is a sense that researchers
submitting their painstakingly acquired datasets for
genome-wide studies are sleep-walking into a desolate
space from which nothing will emerge but a set of p values
conforming pretty much to chance expectation. The
approach we propose aims to mitigate some of the worst
effects of this.
We note that our proposed procedure will do nothing to
highlight the importance of true positive markers which
yield modest p values but which are not yet regarded as
candidates. Once genome scans have been completed and
their results reported it will become necessary to review
findings retrospectively from markers which "become
interesting" after the scan is complete.
Doubtless these issues will be hotly debated, but we hope
that the scheme we propose may represent a useful contri-
bution to this debate and we look forward to the issues
being progressed further.
Methods
The situation we envisage is as follows. We have a dataset
suitable for association studies containing perhaps several
hundred cases and controls. We are about to submit the
sample for a genome wide association scan using, say, 500
K SNPs. For the phenotype under consideration there exist
a few genes for which there is quite strong, but not com-
pletely compelling, evidence for association. Alterna-
tively, there may be genes which are very strong
candidates for other reasons such as the results of expres-
sion studies or pathway analysis. If we were not perform-
ing the genome wide scan we would be typing additional
polymorphisms in these genes. As it is, there are some 40–
50 SNPs in these genes which will be typed in the genome
wide study which have not already been typed. If we were
typing these SNPs in isolation then we would take a result
significant at p < 0.01 as being quite interesting and as
supporting further investigation of this gene, for example
by finding and typing additional polymorphisms within
it. We realise that there are many theoretical problems
with taking such an approach but we believe that it rea-
sonably reflects the interpretation which in practice many
investigators apply when assessing the results of associa-
tion studies. We know that we expect 5 of the 500 K mark-
ers to be significant at p < 0.00001 purely by chance. It is
also possible that some highly significant results from
routinely typed markers may represent true genetic effectsBMC Genetics 2007, 8:20 http://www.biomedcentral.com/1471-2156/8/20
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from hitherto unsuspected regions. We propose that we
would like to achieve a scheme of ranking results such that
a p value of 0.01 from a candidate marker will be consid-
ered similarly to a p value of 0.00001 from a routinely
typed marker in terms of providing an indication of where
further efforts may directed. We recognise that some gen-
uinely associated markers may produce even smaller p val-
ues than this and they will receive favourable
consideration whether or not they are recognised in
advance as occurring in candidate genes.
All of this fits very comfortably into a Bayesian frame-
work. Taking a relatively sceptical view we can say that if a
gene has been the subject of a few positive and some neg-
ative association studies then the probability that that
gene really does influence susceptibility and that a previ-
ously untyped polymorphism within it demonstrates
association might be in the region of 0.1. Then we would
say that the prior odds for a true positive association are
0.1/0.9. Then we could we carry out our genome wide
association study and obtain the likelihood ratio for the
results for a candidate polymorphism to be observed
assuming association compared with the null hypothesis
of no association. To apply a true Bayesian approach we
would need to be able to calculate a Bayes factor consist-
ing of the ratio of the cumulative probability distributions
for the observed results under the alternative and null
hypotheses. Instead, we propose a modified approach
which uses instead the likelihood ratio obtained in the
course of carrying out a likelihood ratio test for heteroge-
neity of allele frequencies between cases and controls.
This test uses the two likelihoods maximised over allele
frequencies under the alternative and null hypotheses. We
use these maximised likelihoods as proxies for the distri-
bution of likelihoods which might be obtained over the
universe of alternative and null hypotheses and which
would be needed in a true Bayesian approach. Multiplying
this likelihood ratio by the prior odds provides an indica-
tion of the posterior odds for the polymorphism to be
associated with the disease. We can do the same thing for
a routinely typed polymorphism but assign it a lower
prior probability of being truly associated. Writing OPr
and OPo for prior and posterior odds and CAND and
ROUT for a candidate or routine polymorphism, we have:
OPoCAND = OPrCAND*LRCAND
OPoROUT = OPrROUT*LRROUT
Our task would then be to select suitable prior odds for
association for a routinely typed marker such that a candi-
date marker with a likelihood ratio yielding a p value of
0.01 would yield similar posterior odds to a routine
marker yielding a p value of 0.00001.
It is helpful to realise that, if one considers allele-wise tests
for association with biallelic markers, there is a simple
relationship between the p value and the likelihood ratio.
Although in practice the test for association used may con-
sist of a Pearson chi-squared statistic derived from a 2 × 2
contingency table it is safe to assume that this will be very
similar to a likelihood ratio statistic calculated as
2*ln(LR) formulated as test for heterogeneity of allele fre-
quencies between cases and controls. In the context of a
genome wide association study this obviates the need to
go through all the genotypings recalculating likelihood
ratios because we can instead use the p values output from
the analysis and convert each into the associated likeli-
hood ratio. We can write p = chidist(x,d) to indicate the p
value associated with a chi-squared statistic of x having d
degrees of freedom and likewise we can write the inverse
function x = chiinv(p,d) to indicate the chi-squared statis-
tic, x, which would yield the stated p value. We can use this
to select appropriate values for the prior odds for candi-
date markers and routine markers by considering the p
values which we wish to make equivalent to each other.
The allele-wise test for association yields a chi-squared test
with one degree of freedom, so that we can state that a sig-
nificance value of p = 0.01 from a candidate marker is
equivalent to a chi-squared of chiinv(0.01,1) = 6.65 and a
likelihood ratio of e6.65/2 = 27.8, while a significance value
of p = 0.00001 from a routine marker is equivalent to a
chi-squared of chiinv(0.00001,1) = 19.5 and a likelihood
ratio of e19.5/2 = 17150. If our aim is to make both sets of
results yield similar posterior odds for association, and if
we assume prior odds for the candidate marker of 0.1/0.9
then we can write:
OPrROUT = OPrCAND * LRCAND/LRROUT
= 0.1/0.9 * 27.8/17150
= 0.00018
As in this case the odds are small they are practically equal
to the probability, so using this scheme we would be
declaring that a marker routinely genotyped as part of a
genome wide association study has a prior probability of
0.00018, or approximately 1 in 5,000, of being truly asso-
ciated. If one considers that there are 25,000 or so human
genes and that several may be involved in the susceptibil-
ity to a particular disease then this estimate may not be
terribly wide of the mark.
Availability and requirements
Software to carry out the conversion from p values to pos-
terior odds is available from http://www.mds.qmul.ac.uk/
statgen/grpsoft.html. It is provided in the form of an Excel
spreadsheet and also as the C source and MSDOS execut-
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PLINK program, such as might be available from a
genome wide association study.
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